Dalton Medicinal Chemistry Partners Signs Agreement with Boehringer Ingelheim
News Mar 26, 2007
Dalton Medicinal Chemistry Partners, the Medicinal Chemistry arm of Dalton Pharma Services, announces the signing of a Medicinal Chemistry agreement with Boehringer Ingelheim (Canada) Ltd.
Dalton Medicinal Chemistry Partners will utilise their medicinal chemistry expertise to design and synthesise novel compounds against a number of antiviral targets selected by Boehringer Ingelheim (Canada) Ltd.
Peter Pekos, President of Dalton Pharma Services, said: "We are pleased to enter this exciting partnership with Boehringer Ingelheim (Canada) Ltd by bringing the added value of our medicinal chemistry capabilities and expertise to their antiviral research projects."
Old age is the greatest risk factor for many diseases, including Alzheimer's disease (AD) and cancer. Geroprotectors are a recently identified class of anti-aging compounds. New research has now identified a unique subclass of these compounds, dubbed geroneuroprotectors (GNPs), which are AD drug candidates and slow the aging process in mice.READ MORE